Studies have revealed that lung cancer patients expressing low levels of both BRCA1 and 53BP1 experienced better prognostic outcomes from chemotherapy [42], and our data imply that downstream DDR-related proteins such as 53BP1 and BRCA1 also display potential as a complementary target to treatment with certain genotoxic anti-cancer agents. The gene discussed is TP53BP1; the disease is lung carcinoma.